SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
Patent Owner
Stats
- 102 US PATENTS IN FORCE
- 0 US APPLICATIONS PENDING
- Jan 07, 2016 most recent publication
Details
- 102 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 2,503 Total Citation Count
- Jun 28, 1974 Earliest Filing
- 350 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
- No Recent Publications to Display
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
9206133 Process for the synthesis of 7-chloro-4-(piperazin-1-yl)-quinolineJun 05, 12Dec 08, 15[C07D]
9114120 Therapeutical method for the treatment of the Leber optic neuropathySep 09, 11Aug 25, 15[A61K, A23L]
9023861 Anticancer combination of artemisinin-based drugs and other chemotherapeutic agentsDec 06, 10May 05, 15[A61K]
8883446 Human long pentraxin 3 expression system and uses thereofJul 20, 10Nov 11, 14[C12P, C12N, C07K]
8853233 Broad-spectrum anti-cancer treatment based on iminocamptothecin derivativesFeb 07, 08Oct 07, 14[A61K]
8822692 Diterpenoid derivatives endowed of biological propertiesJul 26, 13Sep 02, 14[A61K, C07D, C07C]
8778389 Medicament for the treatment of fungal infections particularly aspergillosisApr 28, 05Jul 15, 14[A61K]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2016/0002,244 OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTSAbandonedAug 10, 15Jan 07, 16[A61K, C07D]
2015/0252,120 MODIFIED HYALURONIC ACID DERIVATIVES AND USE THEREOFAbandonedOct 07, 13Sep 10, 15[A61K, A23L, C08B, A61Q]
2014/0294,921 COMPOSITION FOR TIPICAL USE FOR TREATING SKIN DISORDERSAbandonedNov 28, 11Oct 02, 14[A61K]
2014/0079,809 COMPOUNDS USEFUL FOR THE PREVENTION OR TREATMENT OF ACCOMMODATIVE ASTHENOPIAAbandonedNov 18, 13Mar 20, 14[A61K]
8664210 Aminooxime derivatives of 2- and/or 4-substituted androstanes and androstenes as medicaments for cardiovascular disordersExpiredSep 18, 08Mar 04, 14[A61K, C07J]
2013/0236,551 COMBINATION COMPOSITION USEFUL FOR TREATING CARDIOVASCULAR DISEASESAbandonedNov 30, 10Sep 12, 13[A61K]
8530517 Retinoid derivatives endowed with cytotoxic and/or antiangiogenic propertiesExpiredDec 21, 09Sep 10, 13[A61K, C07C]
8518455 Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and riboseExpiredApr 02, 10Aug 27, 13[A61K]
2013/0203,848 COMPOUNDS USEFUL FOR INCREASING NEUROGENESIS IN NEURAL TISSUEAbandonedJun 10, 11Aug 08, 13[A61K]
2013/0122,033 FIMH VACCINE AGAINST URINARY TRACT INFECTIONS (UTI)AbandonedJun 28, 11May 16, 13[A61K]
8383616 Aryl isoxazole compounds with antitumoural activitiesExpiredJun 30, 09Feb 26, 13[A61K, C07D]
2013/0045,940 COMPOSITION COMPRISING AS ACTIVE INGREDIENT L-CARNITINE IN COMBINATION WITH A SOLAR FILTER, FOR THE PREVENTION AND/OR TREATMENT OF PATHOLOGIES OF THE EYE DUE TO ULTRAVIOLET RADIATIONAbandonedFeb 10, 11Feb 21, 13[A61K, A61P]
8377988 Use of L-carnitine or of alkanoyl L-carnitines for the preparation of a physiological supplement or medicament for ophthalmic use in the form of eye dropsExpiredDec 18, 09Feb 19, 13[A61K]
2013/0005,670 COMBINATION COMPOSITION, COMPRISING AS ACTIVE INGREDIENTS L-CARNITlNE OR PROPIONYL L-CARNITlNE, FOR THE PREVENTION OR TREATMENT OF CHRONIC VENOUS INSUFFICIENCYAbandonedFeb 07, 11Jan 03, 13[A61K, A61P]
2012/0258,993 NON-NATURAL MACROCYCLIC AMIDE HDAC6 INHIBITOR COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTSAbandonedSep 21, 10Oct 11, 12[A61K, C07D, A61P]
2012/0252,865 CARBAMATE DERIVATIVES IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISORDERSAbandonedMar 08, 10Oct 04, 12[A61K, C07D, A61P]
Top Inventors for This Owner
Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.